StockData

Arcus Biosciences vs Xencor

RCUS and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RCUS and XNCR compare

Xencor is the larger company, worth 1.2 times as much as Arcus Biosciences ($2.6B against $2.1B).

Xencor grew revenue faster over the last twelve months (−28.6% versus −55.3% for Arcus Biosciences).

Xencor keeps more of each dollar of sales as profit, with a net margin of −156% compared with −393% at Arcus Biosciences.

Xencor scores higher on the StockData Score (5 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRCUSXNCR
Size and price
Market cap$2.1B$2.6B
Share price$16.39$34.50
Change, 1 year−18.3%131%
Change, 5 years−64.6%−2.7%
Beta (5Y)1.13−0.05
Employees601260
StockData Score
Total score35 (better)
Valuation score00
Growth score2 (better)1
Performance score01 (better)
Health score13 (better)
Dividend score00
Valuation
P/S17.8× (better)24.4×
P/B4.5× (better)5.1×
FCF yield−22.8%−8.1% (better)
Fair value$7.34$11.73
Margin of safety−123% (better)−194%
Growth
Revenue growth (TTM)−55.3%−28.6% (better)
Revenue growth, 5Y average25.9% (better)0.47%
Profitability
Operating margin−415%−206% (better)
Net margin−393%−156% (better)
FCF margin−406%−198% (better)
Return on equity−90.8%−29.1% (better)
Return on invested capital–−26.6%
Financial health
Debt / equity–0.21
Interest coverage−44.2×−8.0× (better)
Current ratio3.826.39 (better)
Altman Z-score−0.745.01 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−13.8%–
Shareholder yield−13.8%0.00% (better)
Ownership
Held by institutions96.3%113%
Held by insiders31.7%1.6%
Insider net buying, 12 months−$9.3M−$7.5M (better)
Short interest, % of float15.2%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.